Overview of Dr. Motzer
Dr. Robert Motzer is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of Michigan Medical School and has been in practice 44 years. Dr. Motzer accepts several types of health insurance, listed below. He is one of 500 doctors at Memorial Sloan Kettering Cancer Center and one of 62 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1981 - 1984
- University of Michigan Medical SchoolClass of 1981
Certifications & Licensure
- FL State Medical License 2022 - Present
- NY State Medical License 1983 - 2026
- NJ State Medical License 2019 - 2025
- MI State Medical License 1987 - 1991
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2003-2014
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin Start of enrollment: 1994 Jan 01
- Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Start of enrollment: 1994 Sep 01
- Interferon Alfa in Treating Patients With Advanced Kidney Cancer Start of enrollment: 1998 May 01
- Join now to see all
Publications & Presentations
PubMed
- Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CL...Viktor Grünwald, Rana R McKay, Tomas Buchler, Masatoshi Eto, Se Hoon Park
International Journal of Cancer. 2025-04-01 - 2 citationsGene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.Sari Khaleel, Marlon Perera, Nathan Papa, Fengshen Kuo, Mahdi Golkaram
Urologic Oncology. 2025-03-01 - Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, Patricia Fischer, Robert Goodman
Clinical Genitourinary Cancer. 2025-02-01
Journal Articles
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaRobert Motzer, Thomas E Hutson, Jaime R Merchan, Corina E Dutcus, Rodolfo F Perini, Toni K Choueiri, The New England Journal of Medicine
- Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
- Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Safety, Therapy Management, and Patient-Reported Outcomes in the S-TRAC TrialRobert Motzer, MD, Annals of Oncology
- Join now to see all
Lectures
- Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma2008 Annual Meeting, Chicago, Illinois, USA
- Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell CarcinomaAmerican Society of Clinical Oncology, 2008 Annual Meeting, Chicago, Illinois, USA
Press Mentions
- Frontline Nivolumab Combination Maintains Superiority Over Sunitinib in Kidney CancerFebruary 19th, 2025
- Longest Follow-up for ICI plus TKI Favours Treatment with Avelumab plus Axitinib Combination Versus Sunitinib in Patients with Advanced RCCFebruary 11th, 2025
- Final Analysis of JAVELIN Renal 101 Shows Long-Term Efficacy of Avelumab plus AxitinibJune 10th, 2024
- Join now to see all
Grant Support
- Molecular Basis Of Renal Cell Carcinoma Response To Su11428National Cancer Institute2007–2011
- Clinical Trials And Mentoring In Oncology ResearchNational Cancer Institute1999–2003
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
Great West PPOMultiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: